| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
We examined target therapy of mTOR pathway using human bone and soft tissue sarcoma cell lines (MG63, Nara-H Cell). Our present study suggested that self protective mechanisms involving mTOR inhibitors in sarcoma cells are prevented by the inhibition of autophagy. The combination of an mTOR inhibitor and an autophagy inhibitor may offer effective treatment for sarcoma, as this combination effectively activates apoptotic pathways.
|
